SCHEDULE: StemPoint Capital Discloses 11.4% Stake in Surrozen

StemPoint Capital LP and its affiliates have disclosed a significant 11.4% beneficial ownership stake in Surrozen, Inc., totaling over 1 million shares.

Summary

• StemPoint Capital LP, StemPoint Capital Management GP LLC, and Michelle Ross (collectively, the "Reporting Persons") have jointly filed a Schedule 13G.
• The filing reports beneficial ownership of 1,016,197 shares of Surrozen, Inc.'s Common Stock.
• This aggregate amount represents 11.4% of Surrozen, Inc.'s outstanding Common Stock.
• The ownership includes 686,539 shares and 329,658 shares issuable upon the exercise of warrants.
• The warrants include 195,000 Series E Warrants, 70,158 2024 PIPE Warrants Series A, and 64,500 2024 PIPE Warrants Series B.
• The percentage is calculated based on 8,562,584 shares outstanding as of May 7, 2025, plus the shares issuable from warrants.
• The Reporting Persons hold shared voting power over 963,133 shares and shared dispositive power over 1,016,197 shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: The disclosure of a significant 11.4% stake by a reputable investment firm like StemPoint Capital can be interpreted as a positive signal of investor confidence in Surrozen, Inc., although the filing itself is a neutral regulatory disclosure.

Positives

• A significant 11.4% beneficial ownership stake by StemPoint Capital LP and its affiliates may signal confidence in Surrozen, Inc.'s future prospects from a notable investment firm.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from the issuer.

Industry Context

This filing indicates a significant investment by a capital firm in a biotechnology company, which is a common occurrence in the sector as institutional investors seek to capitalize on growth opportunities in innovative life sciences firms. The substantial stake suggests a long-term passive investment strategy.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may enhance investor confidence and potentially stabilize the stock price due to a large, passive holder.
• Company Management: Awareness of a substantial shareholder may influence strategic decisions, though the filing explicitly states the stake is not for influencing control.

Key Dates

Keywords

Surrozen Inc, StemPoint Capital, Beneficial Ownership, Schedule 13G, Common Stock, Investment Firm, Biotechnology, Warrants